Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The MPN Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Latest Videos The MPN Sessions Subtypes Conferences Features Podcasts Expert Editorial Board

Welcome to The Myeloproliferative Neoplasms (MPN) Channel

VJHemOnc brings you the newest developments in MPNs, including highly anticipated clinical research data, as well as cutting-edge diagnostic and treatment approaches presented at major international congresses. Also explore the latest clonal evolution discoveries, emerging therapies, and novel drug combinations, all in the form of exclusive video interviews, podcasts and roundtable discussions.

Subtypes

Essential Thrombocythemia
Myelofibrosis
Polycythemia Vera
Systemic Mastocytosis
Chronic Myelomonocytic Leukemia
3:58
Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs
Claire Harrison • 13 Jun 2026
2:26
Ropeginterferon may redefine frontline and second-line treatment in ET
Lucia Masarova • 13 Jun 2026
2:30
Novel targeted and anti-inflammatory strategies advance MPN treatment landscape
Lucia Masarova • 13 Jun 2026
1:35
SURPASS-ET: switching to ropeginterferon alfa-2b improves hematologic control in ET
Lucia Masarova • 13 Jun 2026
View All Videos
3:58
Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs
Claire Harrison • 13 Jun 2026
4:52
The hottest updates in MPNs from EHA 2026
Prithviraj Bose • 11 Jun 2026
1:58
Targeting hepcidin in polycythemia vera and myelofibrosis
Ruben Mesa • 12 Jun 2026
3:50
Results from a first-in-human study of a Type II JAK2 inhibitor (AJ1-11095) in myelofibrosis
John Mascarenhas • 13 Jun 2026
View All Videos
1:58
Targeting hepcidin in polycythemia vera and myelofibrosis
Ruben Mesa • 12 Jun 2026
2:17
Exciting advances in the MPN field: novel JAK inhibitors, targeting mutant CALR & more
Naveen Pemmaraju • 12 Jun 2026
2:21
Targeting iron metabolism to improve outcomes in patients with PV
Andrew Kuykendall • 30 Apr 2026
2:45
How may the potential approval of rusfertide impact the treatment landscape for PV?
Andrew Kuykendall • 30 Apr 2026
View All Videos
0:58
Promising therapies and approaches for systemic mastocytosis
Deepti Radia • 12 Jun 2026
4:52
The hottest updates in MPNs from EHA 2026
Prithviraj Bose • 11 Jun 2026
1:17
Advances in the clinical understanding of advanced SM and educational gaps that remain
Deepti Radia • 12 Jun 2026
2:34
Bezuclastinib in advanced systemic mastocytosis: the APEX trial
Daniel DeAngelo • 11 Jun 2026
View All Videos
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
36:15
Myeloid Monthly: breaking news & updates from the Classification Advancement Meeting
Amer Zeidanet al. • 19 Mar 2026
1:36
The potential of using CXCL9 as a prognostic indicator following alloSCT
Shatha Farhan • 17 Feb 2026
1:03
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
Andrew Lane • 6 Dec 2025
View All Videos

Conferences

EHA 2026
ASCO 2026
ESH MPN 2026
EBMT 2026
ASH 2025
SOHO 2025
0:58
Promising therapies and approaches for systemic mastocytosis
Deepti Radia • 12 Jun 2026
3:58
Updated data with INCA033989, a mutant CALR-specific mAb, in patients with MPNs
Claire Harrison • 13 Jun 2026
4:52
The hottest updates in MPNs from EHA 2026
Prithviraj Bose • 11 Jun 2026
1:58
Targeting hepcidin in polycythemia vera and myelofibrosis
Ruben Mesa • 12 Jun 2026
View All Videos
1:51
The optimal frequency and timing of NGS testing in MPNs
Akriti Jain • 27 May 2026
2:21
How may the timing of TP53 mutation acquisition impact outcomes in patients with MPNs?
Akriti Jain • 27 May 2026
2:25
Alterations in calreticulin and CD47 expression dynamics in myeloid malignancies
Ciro Rinaldi • 30 May 2026
0:49
The efficacy and safety of momelotinib in myelofibrosis with a focus on anemia outcomes
Jowan Al-Nusair • 1 Jun 2026
View All Videos
2:06
Deciphering fibrotic niches using NicheSphere in MPNs: study insights and implications
Hélène Gleitz • 22 Apr 2026
2:21
Targeting iron metabolism to improve outcomes in patients with PV
Andrew Kuykendall • 30 Apr 2026
2:53
What evidence led to the FDA accepted NDA for rusfertide in PV?
Andrew Kuykendall • 30 Apr 2026
1:29
Insights into promising hepcidin-modulating agents being explored in PV
Andrew Kuykendall • 30 Apr 2026
View All Videos
2:13
The risk of pulmonary complications in patients with myelofibrosis in the post-transplant setting
Rachel Salit • 2 Apr 2026
2:31
Investigating peri-transplant ruxolitinib as GvHD prophylaxis in patients with myelofibrosis
Rachel Salit • 2 Apr 2026
1:07
Comparing GvHD prophylaxis strategies in patients with MF undergoing matched related donor alloSCT
Patrizia Chiusolo • 23 Mar 2026
3:41
Insights into the updated remission criteria following alloSCT for myelofibrosis
Rachel Salit • 2 Apr 2026
View All Videos
1:03
Early recognition and diagnosis of BPDCN: skin biopsy, markers, and specialist referral
Andrew Lane • 6 Dec 2025
1:10
The potential to “reset” disease progression in MPNs through genome editing
Roman Doll • 7 Dec 2025
3:26
Ruxolitinib plus CDK4/6 inhibitor abemaciclib in previously treated myelofibrosis: Phase I results
Jan Bewersdorf • 16 Dec 2025
2:36
TP53-mutated myeloid malignancies: multi-hit vs single-hit disease and transplant implications
Talha Badar • 7 Dec 2025
View All Videos
1:19
Ongoing developments with JAK inhibitors in MPNs: JAK2 inhibitors
John Mascarenhas • 3 Sep 2025
2:14
Targeting CALR mutations in MPNs: a promising novel immunotherapeutic approach
John Mascarenhas • 4 Sep 2025
10:06
GLP-1 agonists and clinical outcomes in polycythemia vera & MDS
Asfand Yar Cheema • 5 Sep 2025
1:19
The value of fedratinib for the treatment of patients with MF in the second-line setting
Francesco Passamonti • 5 Sep 2025
View All Videos

lucia-masarova
Lucia Masarova
MD
The University of Texas MD Anderson Cancer Center
prithviraj-bose
Prithviraj Bose
MD
The University of Texas MD Anderson Cancer Center

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

Gold Supporter

Takeda

Bronze Supporter

Kartos Therapeutics, Inc.

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

If you are interested in becoming a supporter of The Myeloproliferative Neoplasms Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals